Enlivex Therapeutics (FRA:1BT) Interest Expense : €0.00 Mil (TTM As of Dec. 2023)

Enlivex Therapeutics Interest Expense Chart

Enlivex Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Interest Expense		Get a 7-Day Free Trial					-0.05	-0.01	-0.29	-0.01	-0.01

Enlivex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Enlivex Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enlivex Therapeutics  (FRA:1BT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Enlivex Therapeutics's Interest Expense for the three months ended in Dec. 2023 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was €-5.59 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was €0.63 Mil.

Enlivex Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Enlivex Therapeutics Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Enlivex Therapeutics (FRA:1BT) Business Description